Randomised Controlled Trial Of Intravenous Antivenom Versus Placebo In The Treatment Of Redback Spider Bite
Funder
National Health and Medical Research Council
Funding Amount
$487,440.00
Summary
Redback spiderbite is the most common significant envenoming in Australia and bites by the closely related widow spiders are a major global problem. Despite widespread use of redback spider antivenom, no controlled study has tested its effectiveness. This study aims to test the efficacy of antivenom versus placebo in a large multicentre, randomised controlled trial - RAVE-II. It is of critical importance to determine if an expensive treatment with a known risk of allergic reactions is effective.